The Food and Drug Administration (FDA) is on the search for people who are willing to share their experience with Cannabidiol (CBD), whether it be a simple comment or a full story. This is due in part to a recent statement released by FDA Deputy Commissioner Anna K. Abram: “CBD has been shown to be beneficial in experimental models of several neurological disorders, including seizure and epilepsy.”
In the United States, CBD-containing products are in human clinical testing in three therapeutic area, but no such product are approved by the FDA for marketing for medical purposes. CBD, according to the DEA, is listed as a Schedule I controlled substance under the CSA.
With CBD containing no psychoactive properties, there has been much debate whether it should even be listed as a Schedule I controlled substance and perhaps this new study could help change that ruling.
Many people nationwide can attest to the therapeutic properties of CBD. If you’re one of those people, and you want the FDA to know how CBD has also benefited you, make sure to submit by the deadline.
The deadline to submit is September 13th, 2017 and you may submit two ways: electronically or by mail. If you prefer to remain anonymous, then you must submit by mail only with the heading “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” All submissions received must include the Docket No. FDA-2017-N-4515.
For full information and/or to submit your story, please visit: https://www.regulations.gov/document?D=FDA-2017-N-4515-0001